ANGLE’s Parsortix liquid biopsy getting lots of exposure at world’s biggest cancer conference

Several ANGLE customers have been showcasing Parsortix at the American Association for Cancer Research conference in Atlanta

AACR is the world’s oldest and largest cancer research conference

ANGLE PLC’s (LON:AGL) Parsortix cancer detection system has been showcased by a number of customers at the world’s largest cancer research conference in Atlanta, US.

The University of Athens, Northwestern University and the National Tumour Institute of Milan all presented posters featuring Parsortix at the American Association for Cancer Research (AACR) conference.

Work by the University of Athens was particularly important, ANGLE said, as it demonstrated the “superior performance” of Parsortix in head and neck squamous cell carcinoma (HNSCC) versus antibody-based approaches.

READ: ANGLE’s Parsortix liquid biopsy proving to be more than just a cancer detection device

Several cancer drugs, including Bristol Myers-Squibb’s Opdivo and Merck’s Keytruda, work best in patients with high levels of PD-L1 expression.

In the UoA’s studies, Parsortix was found to be twice as effective at identifying patients with PD-L1 expression.

From a group of 50, Parsortix identified nine with PD-L1 expression whereas the antibody-based test only identified four.

Around one in five patients typically respond to PD-L1 immunotherapies so the Parsortix result was consistent with expected detection levels.

“The multiple poster presentations by ANGLE and its customers at AACR demonstrate new potential applications for ANGLE's Parsortix system and further builds the third-party evidence that Parsortix is a market-leading CTC liquid biopsy solution,” said chief executive Andrew Newland.

“The successful detection of PD-L1 in head and neck cancer opens the potential for collaboration with leading pharma companies with FDA cleared immunotherapy drugs.”

Quick facts: ANGLE PLC

Price: 64.5 GBX

Market: AIM
Market Cap: £111.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...



ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

on 30/10/19

2 min read